AmpliMed PressReleases, AmpliMed is a cancer research chemotherapy corporation with a drug class that features novel mechanisms of action that can defeat MDR and some toxicities

Press Releases

[click the date for a copy of the full text of the press release]

Tucson, Ariz.— September 10, 2008 — AmpliMed Corporation, a cancer therapeutics company, announced today that it has entered into a license agreement with leading Korean-based pharmaceutical company Handok Pharmaceuticals for exclusive rights to its investigational cancer therapeutic Amplimexon® (imexon for injection) in Korea.

Tucson, Ariz.— May 30, 2008— AmpliMed Corporation, a cancer therapeutics company, today announced that data from three clinical trials of Amplimexon® in various cancer types will be presented during the 44^th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place May 30 to June 3, 2008 at McCormick Place in Chicago. Investigators will present final results from a Phase 1/2 trial of Amplimexon (imexon for injection) in metastatic melanoma, updated data from a Phase 1 trial of Amplimexon in combination with docetaxel (Taxotere) in breast, lung and prostate cancer and updated data from a Phase 1 trial of Amplimexon in combination with gemcitabine (Gemzar®) in advanced pancreatic cancer.

Tucson, Ariz.— May 2 , 2008 — Amplimed, a cancer therapeutics company, has announced that patient enrollment is underway in a pPhase II trial of Amplimexon for injection in combination with gemcitabine in patients with advanced pancreatic cancer. The multicenter, randomized Phase I1 trial will evaluate Amplimexon (imexon for injection) plus gemcitabine
versus gemcitabine plus placebo in approximately 124 chemotherapy naive patients with metastatic pancreatic
cancer.

Tucson, Ariz.— January 3 , 2008 — AmpliMed today reported one year survival results from a Phase I/II trial of its lead drug candidate, Amplimexon® (imexon forinjection) in combination with dacarbazine in patients with unresectable stage III or stage IV metastatic malignant melanoma. Results from the full cohort of patients in both the Phase I and Phase II shows a 11.7 month overall mean survival for the entire patient set and a 22 month overall mean survival in the subset of patients with normal LDH levels. This compares favorably to historical controls of 8 months and 10 months, respectively, for patients treated with dacarbazine alone.

Tucson, Ariz. – November 28, 2006 – AmpliMed Corporation today announced a second closing of its Series B Preferred private placement of $8.5 million, raising the total invested in the round to approximately $14.6 million. The Series B was led byBiotech Insight Ventures and included InvestBio Ventures, Valley Ventures and SolsticeCapital, all of whom were previous investors. To date, AmpliMed has raised more than $24 million in financing.

Tucson, Ariz. – November 9, 2006 – AmpliMed today reported final results from the Phase I trial of its lead drug candidate, Amplimexon (imexon for inj.), in patients with advanced solid tumors. The results are being presented by Tomislav Dragovich, MD, PhD, Assistant Professor of Medicine of the Arizona Cancer Center and lead investigator of the study, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held this week in Prague, Czech Republic.

Tucson, Ariz. – September 14, 2006 – AmpliMed today announced interim results from the ongoing Phase I/II clinical trial of its lead drug candidate Amplimexon (imexon, inj.) in combination with the drug dacarbazine (DTIC) in patients with advanced malignant melanoma. The results are being presented by study investigator Dr. Jeffrey. Weber of the USC/Norris Comprehensive Cancer Center at a poster session of September 14^th – 16^th at the congress of Perspectives in Melanoma X and the Third International Melanoma Research Congress.

Tucson, Ariz.— June 2 , 2006 — AmpliMed today announced that the Company has received two awards from Arizona business associations for its outstanding accomplishments and achievements over the past year. At an awards ceremony held on May 31, the cancer drug development company was named “Bioscience Company of the Year” by the Arizona BioIndustry Association (ABA). AmpliMed was also named an “Arizona Company to Watch” by the Arizona Small Business Association (ASBA) during a ceremony on June 1.

Tucson, Ariz.— April 27, 2006 — AmpliMed today announced the initiation of a Phase I study of benzimate (oral solution) in patients with advanced refractory cancer. The study is designed to establish the safety and tolerability of benzimate and is anticipated to enroll approximately 50 patients at a single clinical center in the United States. Information about the study can be obtained by calling AmpliMed at 520-382-0230.

Tucson, Ariz.— March 28, 2006 — AmpliMed today announced that it has begun enrollment of patients in the Phase Ib component of a Phase Ib-II clinical trial to evaluate its lead candidate, Amplimexon (imexon inj.), as a stand-alone therapy in patients with multiple myeloma whose disease has begun to progress following at least two prior therapeutic campaigns, either conventional or experimental. The study is open at two centers in the United States. Information about the study can be obtained by calling AmpliMed at 520-382-0230.

Tucson, Ariz.— January 11, 2006 — AmpliMed Corporation today announced that the European Commission has approved the recommendation of the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) to grant an orphan medicinal product designation for Amplimed’s lead drug, Amplimexon (imexon inj.) for the treatment of ovarian cancer.

Tucson, Ariz.— November 16, 2005 — AmpliMed™ today announced that preliminary results of its Phase I trial of its lead drug candidate, Amplimexon® (imexon inj.), in patients with advanced solid tumors will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held this week in Philadelphia.

October 19, 2005 - AmpliMed today announced that the Company has begun to enroll patients in a new clinical trial that will evaluate its lead candidate, Amplimexon™ (imexon inj.) in combination with the drug docetaxel (Taxotere®, Aventis Pharmaceuticals), in patients with lung, breast and prostate cancer who have failed conventional therapy for their disease.

August 30, 2005 - AmpliMed, a privately-held, Tucson-based pharmaceutical company, today announced that its lead drug Amplimexon ™ (imexon inj.) has been granted orphan drug designation for the treatment of ovarian cancer by the U.S. Food and Drug Administration (FDA).

August 9, 2005 - AmpliMed In-Licenses Novel Cancer Drugs from University of Arizona Foundation Company. AmpliMed Corporation today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) has recommended the granting of orphan medicinal product designation for Amplimed’s lead drug, Amplimexon™ (imexon inj.) for the treatment of pancreatic cancer.

August 5, 2005 - European Committee for Orphan Medical Products Recommends Orphan Drug Status for AmpliMed’s Amplimexon for Pancreatic Cancer. AmpliMed and UAF Technologies and Research, L.L.C. (UTR) today announced that AmpliMed has licensed from UTR certain patents, intellectual property and other assets associated with a portfolio of compounds that has been tested in preclinical studies and may have the potential to treat cancer and certain viral diseases. In particular, one of the compounds in the portfolio, FB642, has shown promise in early clinical trials as an anticancer drug.

July 13, 2005 - AmpliMed Begins Patient Enrollment for Phase I/II Trial of Amplimexon plus Dacarbazine for Treatment of Malignant Melanoma ... AmpliMed today announced that the Company has begun to enroll patients in a new clinical trial that will evaluate its lead candidate, Amplimexon™ (imexon inj.) in combination with the drug dacarbazine (DTIC) in patients with unresectable Stage III or Stage IV malignant melanoma who have not been previously treated with chemotherapy for their metastatic disease. Melanoma is the most serious form of skin cancer and, during the past ten years, the number of cases has increased more rapidly than that of any other cancer.

June 16, 2005 - AmpliMed Corporation today announced the completion of a Series B Preferred private placement of approximately $5 million. Led by Biotech Insight Ventures, previous investors including InvestBio Ventures, Valley Ventures and Solstice Capital also participated in the round. To date, AmpliMed has raised more than $14 million in financing ... Oncology Drug Development Company to Use Funds to Develop and Expand Portfolio of Anticancer Therapies and Bring Drugs into Clinical Trials.

May 10, 2005 - AmpliMed Drug Amplimexon Exhibits Unique Mechanisms of Synergy with Gemcitabine in Human Pancreatic Cancer Cells ... Researchers from the Arizona Cancer Center have made an important breakthrough in understanding the mechanism by which AmpliMed's lead drug, Amplimexon™ (imexon inj.), may synergize with gemcitabine against human pancreatic cancer cells in vitro and in vivo. Amplimexon recently entered a Phase I/II study in combination with gemcitabine in the treatment of patients with previously untreated pancreatic adenocarcinoma. These new data ... suggest that the drug may have broader utility than previously thought.

March 22, 2005 - AmpliMed today announced the promotion of Evan Hersh, M.D. to Executive Vice President, Medical Affairs and Chief Medical Officer and the addition of Wayne Morrison as Director of Finance and Administration.

March 14, 2005 - AMPLIMEXON AmpliMed phase change II ... AmpliMed announced on 3 March 2005 that it has begun patient enrollment into a multi-center US phase I/II trial of imexon injection (AMPLIMEXON) in combination with gemcitabine (GEMZAR) as a therapy for previously untreated advanced pancreatic adenocarcinoma.

March 4, 2005 - AmpliMed initiates phase I/II cancer combo study ... AmpliMed has initiated patient enrollment for a multi-center, phase I/II clinical trial that will study its lead candidate, Amplimexon in combination with gemcitabine as a treatment for patients with previously untreated advanced pancreatic adenocarcinoma.

March 3, 2005 - AmpliMed Initiates Multi-Center, Phase I/II Study of Amplimexon plus Gemcitabine in Patients with Previously Untreated, Advanced Pancreatic Adenocarcinoma ... Study Marks First Human Trial to Evaluate Amplimexon
in Combination with Commonly Prescribed Cancer Therapeutic

March 3, 2005 - New trials set for drug for cancer of pancreas.

May 11, 2004 - AmpliMed Corporation Announces the Successful Completion of Extended Series "A" Financing
$9.25MM Raised to Fund Clinical Development of Novel Cancer Chemotherapies

Dec. 4. 2003 - AmpliMed Receives Orphan Drug Designation for Amplimexon® Injection (Imexon Injection) in the Treatment of Pancreatic Cancer

Sept. 23, 2003 - AmpliMed Corporation Initiates Phase I Clinical Trial of Amplimexon® ... Novel cancer chemotherapy to be studied at Arizona Cancer Care Center

Sept. 16, 2003 - AmpliMed Corporation Raises in excess of $5 Million in Series A Financing ... Funding will be used for clinical development of novel cancer drug, Amplimexon®.

Notice: AmpliMed® and Amplimexon® are registered trademarks of AmpliMed Corporation; Amplizone™ and Inspired Thinking - Advancing Cancer Research™ are trademarks of AmpliMed Corporation